Get the Stockscreener App
0.7581
2.01%
-0.014
Tscan Therapeutics Inc stock is traded at $0.7581, with a volume of 211.22K.
It is down -2.01% in the last 24 hours and down -18.66% over the past month.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$0.772
Open:
$0.768
24h Volume:
211.22K
Relative Volume:
0.34
Market Cap:
$51.38M
Revenue:
$9.14M
Net Income/Loss:
$-124.31M
P/E Ratio:
-0.7919
EPS:
-0.9573
Net Cash Flow:
$-125.43M
1W Performance:
-4.99%
1M Performance:
-18.66%
6M Performance:
-18.83%
1Y Performance:
-58.20%
1-Day Range:
$0.741
$0.789
1-Week Range:
$0.741
$0.7999
52-Week Range:
$0.716
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.7581 | 52.39M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
507.54 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
845.71 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.05 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
345.93 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Equities Analysts Set Expectations for TCRX FY2026 Earnings - MarketBeat
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Tscan Therapeutics stock rating at buy - Investing.com
Tscan Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Nigeria
TScan Therapeutics, Inc. (TCRX) stock price, news, quote and history - Yahoo Finance UK
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Tscan Therapeutics Inc (NASDAQ: TCRX) Stock Price, News & Analysis - kalkine.ca
TScan Therapeutics (NASDAQ:TCRX) Releases Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
TScan Therapeutics Releases Q2 2026 Financial Results - news.alphastreet.com
TScan Therapeutics, Inc. (TCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TScan Therapeutics Q2 Results: Sales Fall 66% YoY, EPS Misses - scanx.trade
TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Form 8K Tscan Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
TScan Therapeutics, Inc. 2Q 2026: Revenue $1.05M, Net loss $30.36M, EPS $(0.23) — 10-Q Summary - TradingView
TScan Therapeutics (TCRX) narrows loss but warns on going-concern outlook and debt - Stock Titan
TScan Therapeutics reports Q2 2026: $1.1M revenue, $30.4M net loss, cash $100.2M - TradingView
TScan Therapeutics Reports $30.4 Million Q2 Net Loss - Quiver Quantitative
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
TScan Therapeutics (TCRX) narrows Q2 2026 loss and doses first patient in Phase 3 ALLOHA-2 trial - Stock Titan
TScan Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results - Quiver Quantitative
TScan Therapeutics Inc (TCRX) Stock News Today - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
TScan doses first patient in phase 3 AML, MDS trial By Investing.com - Investing.com Nigeria
TScan Therapeutics Announces First Patient Dosed in Phase 3 - GlobeNewswire
TScan doses first patient in phase 3 AML, MDS trial - Investing.com
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Income Statement - TradingKey
TScan Therapeutics Inc (TCRX) Cash Flow - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TCRX|TScan Therapeutics Inc|Price:0.765|Chg%:-0.029 - TradingKey
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Balance Sheet - TradingKey
TScan Therapeutics, Inc. Revenue Breakdown – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TCRX|TScan Therapeutics Inc|Price:0.782|Chg%:-0.012 - TradingKey
TScan Therapeutics Inc (TCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
TScan’s TSC-101 Trial: A New Cell Therapy Bet in Transplant Oncology - TipRanks
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
TScan Therapeutics (TCRX) Bounces Off Support, Tests Key Resistance at $0.96Fibonacci Time Zone - dars.gov.et
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
Cellares and Sonoma partner to automate cell therapy manufacturing - Yahoo Finance
TScan Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue PhaseGuidance Update - dars.gov.et
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - AOL.com
A Quick Look at Today's Ratings for TScan Therapeutics(TCRX.US), With a Forecast Between $5 to $7 - Moomoo
TScan Therapeutics (TCRX) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
TScan Therapeutics (TCRX) Q4 2025 earnings summary - Quartr
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Dec 22 '25 |
Buy |
0.90 |
75,500 |
67,950 |
8,012,916 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 23 '25 |
Buy |
0.90 |
6,232 |
5,602 |
8,019,148 |
0.68%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):